{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-027311","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2026-08-12T20:08:26+00:00","discovered_at":"2026-08-12T20:09:07.487133+00:00","generated_at":"2026-08-12T20:09:19.467719+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Talphera Q2 2026 net loss $4.3M; nafamostat CRRT study 75% enrolled","bullets":["Net loss $4.3M ($0.06/share) vs $3.5M loss ($0.10/share) in Q2 2025; cash/investments $17.1M at June 30, 2026.","R&D and SG&A expenses combined $3.9M vs $3.7M in Q2 2025, driven by higher Niyad development costs.","NEPHRO CRRT study of nafamostat 75% enrolled, expected to complete in 2026; all target clinical sites activated.","KDIGO 2026 draft guidelines cite nafamostat as acceptable CRRT anticoagulant; updated market research estimates 200k annual U.S. CRRT procedures (+21%).","Regained Nasdaq compliance with $1 bid price rule."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-027311","json":"https://secwatch.observer/filing/0001437749-26-027311.json","markdown":"https://secwatch.observer/filing/0001437749-26-027311.md","text":"https://secwatch.observer/filing/0001437749-26-027311.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774926027311/0001437749-26-027311-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774926027311/acrx20260811_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:09:19.467719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}